Graves Gilbert Clinic and Labcorp Finalize Strategic Agreement for Lab Operations

Collaboration combines important capabilities, experience and technologies from both organizations to enhance laboratory services

BURLINGTON, N.C., April 3, 2025 –Labcorp (NYSE: LH), a global leader in innovative and comprehensive laboratory services, and Graves Gilbert Clinic have finalized a strategic collaboration in which Labcorp will manage the laboratory operations of Graves Gilbert Clinic’s full-service laboratories in Bowling Green and Glasgow, Kentucky. This relationship is designed to improve access to high-quality diagnostics while ensuring efficient, high-quality care for patients and providers across South Central Kentucky.  

By leveraging Labcorp’s advanced testing capabilities and Graves Gilbert Clinic’s deep commitment to patient care, the collaboration will introduce newer technology, enhanced laboratory and diagnostic services—all while keeping care local and convenient.

“Labcorp is committed to continuing Graves Gilbert Clinic’s long tradition of delivering high-quality care while providing access to our innovative services and diagnostics,” said Amy Rhine-Pallas, Senior Vice President of Labcorp’s North Central Division. “Through our combined expertise, we aim to enhance the patient and provider experience to meet the evolving needs of the community."

Mike D’Eramo, Chief Executive Officer of Graves Gilbert Clinic, added: “We are excited to collaborate with a global partner like Labcorp. Their partnership will help us achieve our ongoing goals to lower costs, improve access, and remain the high-value provider for our patients.”

Both organizations have been working together in support of a seamless transition for patients and providers. 

About Labcorp
Labcorp (NYSE: LH) is a global leader of innovative and comprehensive laboratory services that helps doctors, hospitals, pharmaceutical companies, researchers and patients make clear and confident decisions. We provide insights and advance science to improve health and improve lives through our unparalleled diagnostics and drug development laboratory capabilities. The company's nearly 70,000 employees serve clients in approximately 100 countries, provided support for more than 75% of the new drugs and therapeutic products approved in 2024 by the FDA, and perform more than 700 million tests annually for patients around the world. Learn more about us at www.labcorp.com.

SOURCE Labcorp

Media, Alissa Lawver, [email protected]; Investors, Nickolo Russo, [email protected]